Page 5 - Global External News Today

Investegate announcements from ,

Investegate announcements from INVENTIVA, Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment

Investegate announcements from INVENTIVA, Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

Investegate announcements from INVENTIVA, Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

Daix (France), Long Island City (New York, United States), November 21, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral

Investegate announcements from INVENTIVA, Inventiva announces a new Director of the Board of Directors

Investegate announcements from INVENTIVA, Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

Daix (France), Long Island City (New York, United States), October 21, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small

Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from...